Non-selective protease activated receptor 4 ALA120THR isoform antagonist

A pharmaceutical composition for treating a cardiovascular or coronary heart disease comprising a compound selected from the group consisting of a compound of Formula I:

• wherein in Formula I:
• R is nitrogen or carbon;
• R1 is selected from the group consisting of a hydrogen, an alkyl, a trifluoromethyl, a methyloxyphenyl, a phenyl, a C1-C3 phenylalkyl, a halogenated phenyl, a halogenated C1-C3 phenylalkyl, a trifluoromethyloxy, a trifluoromethyloxyphenyl, and a C1-C3 pyridinylalkyl;
• R2 is selected from the group consisting of a C1-C3 alkyl alcohol optionally substituted with a C1-C3 alkoxyphenyl, a C1-C3N-alkylmethanamine, a C1-C3alkoxymethyl, a C1-C3 phenylalkoxymethyl, a C1-C3 cyclopropylalkoxymethyl, and a methoxyethoxymethyl;
• and
• R3 is a phenyl or a methoxypyridinyl;
• R4 is a trifluoromethyl;
• and
• a pharmaceutically acceptable carrier.

A method of treatment of a patient having cardiovascular or coronary heart disease comprising administering to said patient an effective amount of a composition comprising a compound selected from the group consisting of a compound of Formula I:

• wherein in Formula I:
• R is nitrogen or carbon;
• R1 is selected from the group consisting of a hydrogen, a trifluoromethyl, a methyloxyphenyl, a phenyl, a C1-C3 phenylalkyl, a halogenated phenyl, a halogenated C1-C3 phenylalkyl, a trifluoromethyloxy, a trifluoromethyloxyphenyl, and a C1-C3 pyridinylalkyl;
• R2 is selected from the group consisting of a C1-C3 alkyl alcohol optionally substituted with a C1-C3 alkoxyphenyl, a C1-C3 N-alkylmethanamine, a C1-C3alkoxymethyl, a C1-C3 phenylalkoxymethyl, a C1-C3 cyclopropylalkoxymethyl, and a methoxyethoxymethyl;
• and
• R3 is a phenyl or a methoxypyridinyl;
• R4 is a trifluoromethyl;
• and a pharmaceutically acceptable carrier.